Gensight Biologics SA
PAR:SIGHT

Watchlist Manager
Gensight Biologics SA Logo
Gensight Biologics SA
PAR:SIGHT
Watchlist
Price: 0.2765 EUR -0.36%
Market Cap: 32m EUR
Have any thoughts about
Gensight Biologics SA?
Write Note

Gensight Biologics SA
EPS (Diluted)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Gensight Biologics SA
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
Gensight Biologics SA
PAR:SIGHT
EPS (Diluted)
€0
CAGR 3-Years
16%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
EPS (Diluted)
€0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Innate Pharma SA
PAR:IPH
EPS (Diluted)
€0
CAGR 3-Years
-12%
CAGR 5-Years
N/A
CAGR 10-Years
-8%
G
Genfit SA
PAR:GNFT
EPS (Diluted)
€0
CAGR 3-Years
22%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
EPS (Diluted)
-€2
CAGR 3-Years
-23%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Eurobio Scientific SA
PAR:ALERS
EPS (Diluted)
€0
CAGR 3-Years
-55%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Gensight Biologics SA
Glance View

Market Cap
32m EUR
Industry
Biotechnology

GenSight Biologics SA is a clinical-stage gene therapy company. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2016-07-13. The firm develops and commercializes gene therapy-based treatments of retinal degenerative diseases. The company develops approaches to prevent retinal degeneration in selected pathological conditions and to restore vision in patients suffering from low vision or blindness. The firm intends notably to develop a gene replacement therapy for Leber's hereditary optic neuropathy (LHON) and an optogenetic therapy for retinitis pigmentosa (RP).

SIGHT Intrinsic Value
0.1634 EUR
Overvaluation 41%
Intrinsic Value
Price

See Also

What is Gensight Biologics SA's EPS (Diluted)?
EPS (Diluted)
-0.4 EUR

Based on the financial report for Jun 30, 2024, Gensight Biologics SA's EPS (Diluted) amounts to -0.4 EUR.

What is Gensight Biologics SA's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
23%

Over the last year, the EPS (Diluted) growth was 56%. The average annual EPS (Diluted) growth rates for Gensight Biologics SA have been 16% over the past three years , 23% over the past five years .

Back to Top